OmniComm Systems, the US-based electronic data capture (EDC) specialist that bought the EDC business of eResearch Technology (ERT) in June, has made good on its declared ambition to pursue further acquisitions, taking over the EDC assets of UK-based clinical software provider Logos Technologies for an undisclosed sum.

Following the ERT deal, OmniComm retained Emerging Growth Equities as a financial advisor “to assist in evaluating strategic alternatives with a focus on acquisitions that may be available to the Company”.

The Logos Technologies assets will be managed by OmniComm’s UK subsidiary, OmniComm Ltd. Logos’ software is used to collect data from Phase I clinical trials and complements OmniComm’s TrialMaster platform, which is mainly used for later-stage trials.

The acquired Logos products cover all aspects of the Phase I process, from subject recruitment and workflow management to laboratory sample management, OmniComm noted.

“Regular EDC solutions for later-stage trials do not include a proactive data collection system, which is imperative for the very time-controlled data collection during many early-stage clinical studies,” it commented, adding that there are only three widely known Phase I systems in the world capable of doing this.

According to market research firm Health Insights, the Phase I sector is one of the fastest growing segments of the clinical research industry, OmniComm pointed out. The electronic data capture market for Phase I studies alone is forecast by Health Insights to reach US$120 million in 2010.

President and chief executive officer Cornelis Wit said the Logos assets would broaden the scope of OmniComm’s integrated eClinical solutions offering. “Only a very small number of EDC companies specialise in the Phase I market”, he commented.

“This, combined with our recent acquisition of eResearch Technology’s data capture unit, positions us well to offer our clients a wide array of state-of-the art, cost-effective tools to capture and track outcomes of clinical trials.”